🇺🇸 FDA
Pipeline program

Tolvaptan

156-KOB-1101i

Approved small_molecule terminated

Quick answer

Tolvaptan for Hyponatremia and Extracellular Fluid in Cirrhotic is a Approved program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
Otsuka Beijing Research Institute
Indication
Hyponatremia and Extracellular Fluid in Cirrhotic
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials